Transmedics Group, Inc. (TMDX) fundamentals score
Transmedics Group is a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It developeds the OCS to replace a decades-old standard of care that it believes is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide.
Electromedical & Electrotherapeutic Apparatus · Healthcare · Listed on NASDAQ
Overall: 6.9 out of 10, Good long-term fundamentals
- Growth: 7.2/10
- Profitability: 6.1/10
- Financial health: 7.3/10
- Earnings quality: 5.6/10
- Valuation: 8.8/10
Scores are calculated from Transmedics Group, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10